secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001628280-26-007114
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears Precision BioSciences' IND for PBGENE-DMD gene editing therapy for DMD
--------------------------------------------------------------------------------

- FDA Study May Proceed allows initiation of clinical trial site activation for Phase 1/2 FUNCTION-DMD study in ambulatory DMD patients.
- PBGENE-DMD is an in vivo gene excision approach targeting mutations in exons 45-55, covering ~60% of DMD patients.
- Aims to restore near full-length dystrophin (80% of full-length), larger than existing micro-dystrophin constructs (~34%).
- Company plans to activate first US clinical site in the first half of 2026.
- Virtual investor event scheduled for March after MDA conference with key opinion leaders and patient advocates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026007114/0001628280-26-007114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026007114/dtil-20260211.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-007114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer